GlaxoSmithKline Plc said on Wednesday the U.S health regulator approved its lung disease drug Trelegy Ellipta for expanded use, making it the first inhaler delivering three drugs at once to be ...
SUNRISE, Fla., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, ...
Breo Ellipta is a prescription medication used to treat asthma and chronic obstructive pulmonary disease (COPD). It combines two active ingredients, fluticasone furoate and vilanterol, to help reduce ...
On Wednesday, GSK Plc (NYSE:GSK) announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all its asthma and chronic obstructive pulmonary disease (COPD) ...
WASHINGTON (AP) – A panel of respiratory experts voted Wednesday in favor of approving an experimental inhaler drug from GlaxoSmithKline and Theravance for treating chronic lung disease. A majority of ...
An inhaler is a method of administering medication for COPD. You only need to breathe into the L-shaped gadget for it to transport the drug to your lungs. Separate inhalers may be used for each ...
Adherium, a New Zealand-based maker of connected respiratory medical devices, has received the US Food and Drug Administration's 510(k) clearance for connecting its digital monitoring platform with ...
The Food and Drug Administration has cleared a three-drug inhaler from GlaxoSmithKline for use in adult asthma patients, an approval the company believes will help differentiate its product in the ...
GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) today announced the acceptance of a regulatory submission seeking an additional indication for the use of once-daily, single-inhaler triple therapy, ...
GlaxoSmithKline and Innoviva, Inc. announced headline results from the phase 3 CAPTAIN study demonstrating that once-daily single inhaler triple therapy with fluticasone furoate, umeclidinium and ...
A combination drug-device therapy developed by GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) for asthma, Trelegy Ellipta, met the primary endpoint in its pivotal trial, the companies said last ...